undamentalytics Newsletter
Sign in

Progyny, Inc. income statement

In fiscal 2025, Progyny, Inc. reported revenue of $1.29bn, up 10.4% on the year before, operating income of $85.3m (a 6.6% margin) and net income of $58.5m, or $0.65 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue491052303455017871,0891,1671,2891,311
Cost of revenue4186184275388620850914984989
Gross profit7194670112167239253304322
Research and development————————1012
Selling and marketing471215204659647271
General and administrative141624476098117122147139
Operating income−11−31083223626785112
Net interest income−1−0−00013———
Income before tax−12−7−993224718395120
Income tax−0−20−38−33−69293741
Net income−121−946663062545979
Diluted EPS−$0.47$0.01−$0.08$0.47$0.66$0.30$0.62$0.57$0.65$0.91
Diluted shares (average)28m28m104m99m100m100m101m95m90m87m
EBITDA−9−212103425647190118

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: HQY vs PGNYGH vs PGNYADUS vs PGNYPGNY vs PIII

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Progyny, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Progyny, Inc.